AARD (Aardvark Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on AARD (Aardvark Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

AARD

Aardvark Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
Nov 13, 2025
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Nov 11, 2025
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
Nov 4, 2025
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Nov 3, 2025
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November
Nov 3, 2025
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
Oct 22, 2025
Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment
Oct 17, 2025
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
Oct 8, 2025
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
Sep 23, 2025
LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought
Sep 8, 2025
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
Aug 27, 2025
Retail investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest stockholders and were hit after last week's 11% price drop
Aug 12, 2025
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
Aug 12, 2025

Reviews